产品名称

普卡必利

CAS NO

179474-85-2

中文别名

普卡比利琥珀酸盐;丁二酸;琥珀酸普卡必利;4-氨基-5-氯-2,3-二氢-N-[1-(3-甲氧基丙基)-4-哌啶基]-7-苯并呋喃甲酰胺;

英文名称

4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide,butanedioic acid

英文别名

Resolor (TN); Prucalopride succinate; Prucalopride Succinat; Prucalopride succinate (USAN); Resolor; BUTANEDIOIC ACID 4-AMINO-5-CHLORO-2,3-DIHYDRO-N-[1-(3-METHOXYPROPYL)-4-PIPERIDINYL]-7-BENZOFURANCARBOXAMIDE; 查看更多英文别名 收起

分子式

C22H32ClN3O7

分子量

485.95800

EINECS

680-639-5

熔点

>196°C (dec.)

沸点

毒性

Product Description specification: English name Prucalopride Succinate CAS NO. 179474-85-2 Synonym Butanedioic acid 4-amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4 -piperidinyl]-7-benzofurancarboxamide;Prucalopride Succinate Molecular Weight 485.9649 Molecular Formula C22H32N3O7Cl Assay 99% introduction : Prucalopride is a drug acting as a selective, high affinity 5-HT4 receptor agonist which targets the impaired motility associated with chronic constipation, thus normalising bowel movements.Prucalopride was approved for use. Mechanism of action: Prucalopride, a first in class dihydro-benzofuran-carboxamide, is a selective, high affinity serotonin (5-HT4) receptor agonist with enterokinetic activities. Prucalopride alters colonic motility patterns via serotonin 5-HT4 receptor stimulation: it stimulates colonic mass movements, which provide the main propulsive force for defecation. The observed effects are exerted via highly selective action on 5-HT4 receptors:prucalopride has >150-fold higher affinity for 5-HT4 receptors than for other receptors.Prucalopride differs from other 5-HT4 agonists such as tegaserod and cisapride, which at therapeutic concentrations also interact with other receptors (5-HT1B/D and the cardiac human ether-a-go-go K+ or hERG channel respectively) and this may account for the adverse cardiovascular events that have resulted in the restricted availability of these drugs.Clinical trials evaluating the effect of prucalopride on QT interval and related adverse events have not demonstrated significant differences compared with placebo. Efficacy: The primary measure of efficacy in the clinical trials is three or more spontaneous complete bowel movements per week; a secondary measure is an increase of at least one complete spontaneous bowel movement per week. Further measures are improvements in PAC-QOL (a quality of life measure) and PAC-SYM (a range of stool, abdominal, a